Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence



Rating:

Share or cite this content

Citations should be made in the following way:
S. Birring (London, United Kingdom), J. Smith (Manchester, United Kingdom), A. Morice (Hull, United Kingdom), M. Sher (Largo, United States of America), J. Hull (London, United Kingdom), A. Goldsobel (San Jose, United States of America), S. Lanouette (Montreal, Canada), E. Li (Wilmington, United States of America), L. Harvey (Montreal, Canada), C. Bonuccelli (Wilmington, United States of America). Improvements in cough severity and cough-related quality of life in a phase 2 trial (RELIEF) with the P2X3 antagonist BLU-5937 in refractory chronic cough (RCC). 1199

Member's Comments

No comment yet.

Related content which might interest you: Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Source: ERJ Open Res, 6 (4) 00284-2020; 10.1183/23120541.00284-2020 Year: 2020 Patient-reported chronic cough severity over 52 weeks in two phase 3 trials of gefapixant Source: Virtual Congress 2021 – Patient-reported outcome measures (PROMs): easy tools in the management of chronic respiratory diseases Year: 2021 The relationship between cough counts and cough-specific quality of life in patients with chronic cough Source: Eur Respir J 2004; 24: Suppl. 48, 47s Year: 2004 The relationship between dyspnea and detection of depression in COPD patients (pts) Source: International Congress 2015 – Different data in COPD Year: 2015 Analysis of the level of dyspnea and health-related quality of life (HRQoL) in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002 Influence of tiotropium bromide (TB) on the severity of clinical, functional symptoms and health-related quality of life (HRQL) in COPD patients (pts) Source: Annual Congress 2011 - COPD management Year: 2011 Relationship between dyspnea levels and health-related quality of life (HRQoL) in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 240s Year: 2003 Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 Impact on objective cough severity by continuous positive airway pressure (CPAP) in subjects with chronic cough and obstructive sleep apnoea – A randomized controlled trial Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura Year: 2011 How to quantify coughing: correlations with quality of life in chronic cough Source: Eur Respir J 2008; 32: 175-179 Year: 2008 NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 A randomised controlled trial of cognitive behavioural therapy (CBT) delivered by respiratory nurses to reduce anxiety in chronic obstructive pulmonary disease (COPD). (Trial registration - ISCRCTN55206395) Source: International Congress 2016 – Respiratory nursing research: opening new perspectives on patient experiences Year: 2016 The effect of baseline factors on treatment response with MK-7264, a P2X3 antagonist, in refractory chronic cough. Source: International Congress 2018 – Management of chronic cough and respiratory muscle dysfunction Year: 2018 Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Assessment of quality of life, anxiety and depression in patients with chronic cough Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Patient-reported outcomes (PROs) and reliever use in Japanese and European patients with chronic obstructive pulmonary disease receiving formoterol 4.5 and 9μg twice daily: Results of the OCEAN phase III study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Late Breaking Abstract - The neurokinin-1 receptor antagonist orvepitant improves chronic cough symptoms: results from a Phase 2b trial Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 Influence of smoking on quality of life (QoL) and dyspnoea in patients with COPD Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD Year: 2008 Dupilumab improves patient-reported outcomes in chronic sinusitis with nasal polyps patients with comorbid asthma: Results from a phase 2a trial Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016